FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biochemistry, particularly to anti-human CSF-1R antibodies, methods for producing them, pharmaceutical compositions containing the above antibodies, and applications thereof. There are disclosed versions of the CSF-1R-binding antibody, as well as a pharmaceutical composition for treating CSF-1R-mediated diseases. There are also disclosed applications of the above antibody and the method for producing them with the necessary nucleic acid, expression vector and host cell.
EFFECT: invention enables inhibiting the CSF-1R-expressing cell growth effectively.
22 cl, 13 dwg, 11 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF | 2012 |
|
RU2658603C2 |
| MACROPHAGE ACTIVATION MODULATION | 2012 |
|
RU2639553C2 |
| ANTIBODIES TO HUMAN CSF-1R AND USE THEREOF | 2011 |
|
RU2617971C2 |
| IL-17 ANTAGONIST ANTIBODIES | 2005 |
|
RU2426741C2 |
| ANTIBODY AGAINS CSF-1R | 2012 |
|
RU2621859C2 |
| ANTI-GM-CSF ANTIBODIES AND USING THEM | 2006 |
|
RU2447085C2 |
| ANTI-SIRPα ANTIBODY AND USE THEREOF | 2021 |
|
RU2822496C1 |
| ANTI-CXCR4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | 2014 |
|
RU2675516C2 |
| CELL DAMAGE INDUCING THERAPEUTIC MEDICINAL PRODUCT FOR ANTICANCER THERAPY | 2017 |
|
RU2746754C2 |
| ANTIBODIES TO HUMAN CSF-1R AND USE THEREOF | 2011 |
|
RU2617966C2 |
